$ANIX

Titterton Lewis H jr purchased $42K of ANIX

Titterton Lewis H jr purchased 12,000 shares of Anixa Biosciences Inc (ANIX) at $3.47 on 2026-07-20.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jul 20, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

A new insider open-market purchase was disclosed at a specific price and share count, which can modestly influence sentiment but does not, by itself, change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without additional operational catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the purchase is part of a broader pattern; traders should compare with prior Form 4 activity and overall volume/liquidity.

Relevance 4/10Novelty 5/10Timing: Filed on 2026-07-20, same day as the reported purchase date.

Background

This is an SEC Form 4 insider transaction for Anixa Biosciences, reported by a director.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Director Titterton Lewis H jr filed a Form 4 open-market purchase of 12,000 ANIX shares at $3.4700 on 2026-07-20.

Expected impact

Likely limited near-term impact; may slightly support sentiment if traders treat insider buying as a signal.

Evidence & confidence

Form 4 confirms a new transaction today, yet it does not include guidance, trial results, contracts, or other company-specific fundamentals that typically drive repricing.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide information.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by diversification, liquidity needs, or non-informational factors, especially without a 10b5-1 plan.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction, ticker ANIX.

  • Titterton Lewis H jr

    Director who reported an open-market purchase of 12,000 shares.

Related articles